Acorda Therapeutics

$1.78 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Acorda Therapeutics

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.

Stock Analysis

last close $1.86
1-mo return -23.8%
3-mo return -57.3%
avg daily vol. 110.89T
52-week high 8.15
52-week low 1.78
market cap. $21M
forward pe -
annual div. -
roe -69.6%
ltg forecast -
dividend yield -
annual rev. $130M
inst own. 28.3%
baraka

Subscribe now for daily local and international financial news

Subscribe